Background: Orexin-A, also known as hypocretin, is a neuropeptide implicated in appetite and sleep regulation. Because the obstructive sleep apnea syndrome (OSAS) is characterized by obesity and excessive daytime sleepiness, we hypothesized that orexin-A levels may be abnormal in patients with OSAS. Further, since treatment with continuous positive airway pressure (CPAP) in patients with OSAS is very effective in normalizing daytime sleepiness, we also hypothesized that the chronic use of CPAP may influence plasma levels of orexin-A in these patients. Objective: To evaluate plasma levels of orexin-A in patients with OSAS and the effect of CPAP treatment. Patients and Methods: We compared the plasma levels of orexin-A in 13 healthy controls, 27 untreated patients with OSAS and 14 patients treated with CPAP during at least 1 year (4.5 ± 0.5 h/night; mean ± SEM). All patients had severe OSAS (apnea-hypopnea index, 57 ± 4 h–1). Results: Orexin-A plasma levels were significantly lower in untreated (9.4 ± 1.9 pg·ml–1, p < 0.01) and treated patients with OSAS (4.2 ± 1.5 pg·ml–1, p < 0.001) than in healthy subjects (20.6 ± 4.5 pg·ml–1). In untreated patients, orexin-A levels were not significantly related to daytime somnolence assessed by Epworth scale (r = –0.18, p = 0.37) or the body mass index (r = –0.13, p = 0.52). Conclusions: Orexin-A plasma levels are abnormally low in patients with OSAS, independently of the level of somnolence and/or presence of obesity. These results suggest that these low orexin-A levels may be related to the pathogenesis of OSAS.

Keywords:
Continuous positive airway pressure, Neuropeptides, Obesity, Orexins, Sleepiness
1.
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235.
2.
Carrera M, Barbé F, Sauleda J, Tomás M, Gómez C, Agustí AG: Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am J Respir Crit Care Med 1999;159:1960–1966.
3.
Kraiczi H, Hedner J, Dahlöf P, Ejnell H, Carlson J: Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999;22:61–67.
4.
Koos BJ, Maeda T, Jan C: Adenosine A(1) and A(2A) receptors modulate sleep state and breathing in fetal sheep. J Appl Physiol 2001;91:343–350.
5.
Marik PE: Leptin, obesity, and obstructive sleep apnea. Chest 2000;118:569–571.
6.
Sartin JL, Dyer C, Matteri R, Buxton D, Buonomo F, Shores M, et al: Effect of intracerebroventricular orexin-A-B on food intake in sheep. J Anim Sci 2001;79:1573–1577.
7.
Taheri S, Ward H, Ghatei M, Bloom S: Role of orexins in sleep and arousal mechanisms. Lancet 2000;355:847.
8.
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin XY, et al: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin-A) receptor 2 gene. Cell 1999;98:365–376.
9.
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al: Narcolepsy in orexin-A knockout mice: Molecular genetics of sleep regulation. Cell 1999;98:437–451.
10.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E: Hypocretin (orexin-A) deficiency in human narcolepsy. Lancet 2000;355:39–40.
11.
Higuchi S, Usui A, Murasaki M, Matsushita S, Nishioka N, Yoshino A, et al: Plasma orexin-A is lower in patients with narcolepsy. Neurosci Lett 2002;318:61–64.
12.
Ballester E, Badia JR, Hernández L, Carrasco E, De Pablo J, Fornas C, et al: Evidence of the effectiveness of continuous positive airway pressure in the treatment of sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:495–501.
13.
Barbé F, Amilibia J, Capote F, Duran J, Mangado NG, Jimenez A, et al: Diagnostico del sindrome de apneas obstructivas durante el sueño. Informe de consenso del Area de Insuficiencia Respiratoria y Transtornos del Sueño. Arch Bronconeumol 1995;31:460–462.
14.
Kapuniai LE, Andrew Dj, Crowell DH, Pearce JW: Identifying sleep apnea from self-reports. Sleep 1988;11:430–436.
15.
Johns MW: A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 1991;14:540–545.
16.
Nishijima T, Sakurai S, Arihara Z, Takahashi K: Plasma orexin-A-like immunoreactivity in patients with sleep apnea hypopnea syndrome. Peptides 2003;24:407–411.
17.
Igarashi N, Tatsumi K, Nakamura A, Sakao S, Takiguchi Y, Nishikawa T, et al: Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome. Chest 2003;124:1381–1385.
18.
Sakurai S, Nishijima T, Takahashi JS, Yamauchi K, Arihara Z, Takahashi K: Clinical significance of daytime plasma orexin-A-like immunoreactivity concentrations in patients with obstructive sleep apnea-hypopnea syndrome. Respiration 2004;71:380–384.
19.
Sutcliffe JG, de Lecea L: The hypocretins: Exitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 2000;62:161–168.
20.
Xi MC, Morales FR, Chase MH: Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res 2001;901:259–264.
21.
Schwartz MW: Orexins and appetite: The big picture of energy homeostasis gets a little bigger. Nat Med 1998;4:385–386.
22.
Kotz CM, Teske JA, Levine JA, Wang CF: Feeding and activity induced by orexin-A A in the lateral hypothalamus in rats. Regul Pept 2002;104:27–32.
23.
Isse T, Ueta Y, Serino R, Noguchi J, Yamamoto Y, Nomura M, Shibuya I, Lightman SL, Yamashita H: Effects of leptin on fasting-induced inhibition of neuronal nitric oxide synthase mRNA in the paraventricular and supraoptic nuclei of rats. Brain Res 1999;846:229–235.
24.
López M, Seoane L, García MD, Lago F, Casanueva FF, Señarís R, et al: Leptin regulation of prepro-orexin-A and orexin-A receptor mRNA levels in the hypothalamus. Biochem Biophys Res Commun 2000;269:41–45.
25.
Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al: Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–1158.
26.
Chin KZ, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, et al: Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999;100:706–712.
27.
Arihara Z, Takahashi K, Murakami O, Totsune K, Sone M, Satoh F, et al: Immunoreactive orexin-A in human plasma. Peptides 2001;22:139–142.
28.
Sweet DC, Levine AS, Billington CJ, Kotz CM: Feeding response to central orexins. Brain Res 1999;821:535–538.
29.
Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW: Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 2002;26:274–276.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.